logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
K

Kenneth J. O’Byrne

Princess Alexandra Hospital

91H-index
1.2KPaper Count
4.9WCitation Count
Published Papers 212
Publication Date
logo
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)
errInternational Journal of Radiation Oncology*Biology*Physics
IF0
err2025-12-19
err0
PREAI
errGargi Kothari; Kenneth J. O’Byrne; Chris Brown; Martin R. Stockler; Mariya Walker; Nicholas Hardcastle; Tomas Kron; Hien V. Le; Suzanne Kosmider; Laird Cameron; Louis Lao; Paul Mitchell; Shankar Siva
errShare
errSave
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design
errFuture Oncology
IF2.6
err2025-12-13
err0
errOAAI
errMartin Reck; Shun Lu; Kenneth J. O’Byrne; Carlos Barrios; Dmitri Pavlov; Fabian Tay; Marcelo V. Negrao
errShare
errSave
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer
errFUTURE ONCOLOGY
IF2.6
err2025-12-01
err0
PREAI
errO'Byrne, Kenneth; Esteban, Emilio; Lee, Cheen Leng; Hegmane, Alinta; Volovat, Constantin; Lo Russo, Giuseppe; Ziogas, Dimitrios; Atmaca, Akin; Sebastian, Martin; Majem, Margarita
errShare
errSave
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
errLung Cancer
IF4.4
err2025-11-24
err0
PREAI
errMarliese Alexander; Malinda Itchins; Jonathan Felthun; Adnan Nagrial; Lauren J. Brown; Kenneth O’Byrne; Antony J. Mersiades; Brett G.M. Hughes; Lydia Warburton; Benjamin Y. Kong; Melissa Moore; Prunella Blinman; Samantha Bowyer; Timothy Clay; Tim Spelman; Benjamin J. Solomon; Steven Kao
errShare
errSave
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results
errCancer Chemotherapy and Pharmacology
IF2.3
err2025-10-08
err0
errOAAI
errJayesh Desai; Sanjeev Deva; Bo Gao; Kunyu Yang; Kenneth J. O’Byrne; Meili Sun; Tianshu Liu; Tarek Meniawy; Xinmin Yu; Mark Voskoboynik; Diwakar Davar; Marco Matos; Shiangjiin Leaw; Tahmina Rahman; Xiaofei Qu; Hugh Giovinazzo; Xin Chen; Yan Dong; Daphne Day
errShare
errSave
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
errJournal of Thoracic Oncology
IF20.8
err2025-06-03
err0
PREAI
errSolange Peters; Meredith M. Regan; Luis G. Paz-Ares; Martin Reck; Hossein Borghaei; Kenneth J. O’Byrne; Julie R. Brahmer; John R. Penrod; Janice Li; LaRee Tracy; Yong Yuan; Judith Bushong; Adam Lee; Laura J. Eccles; Saurabh Ray; Suresh S. Ramalingam
errShare
errSave
Rearranged during transfection (RET) lung cancer - Update on targeted therapies
errLUNG CANCER
IF4.4
err2025-02-01
err0
PREAI
errMullally, W. J.; O'Leary, C. G.; O'Byrne, K. J.
errShare
errSave
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
errONCOLOGIST
IF4.2
err2025-01-23
err0
errOAAI
errSkoulidis, Ferdinandos; Li, Bob T.; Hochmair, Maximilian; Govindan, Ramaswamy; Vincent, Mark; van der Wekken, Anthonie J.; Reguart Aransay, Noemi; O'Byrne, Kenneth J.; Griesinger, Frank; Nishio, Makoto; Lindsay, Colin; Reinmuth, Niels; Paulus, Astrid; Papakotoulas, Pavlos; Kim, Sang-We; Ferreira, Carlos Gil; Pasello, Giulia; Duruisseaux, Michael; Gennatas, Spyridon; Dimou, Anastasios; Mehta, Bhakti; Kormany, William; Nduka, Chidozie; Sylvester, Brooke E.; Ardito-Abraham, Christine; Wang, Yang; de Langen, Adrianus Johannes
errShare
errSave
6y update of 1L nivolumab plus ipilimumab (N plus I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227
errANNALS OF ONCOLOGY
IF65.4
err2024-10-01
err0
PREAI
errNishio, M.; Ramalingam, S. S.; Ciuleanu, T.; Caro, R. Bernabe; Mizutani, H.; Lee, J.; Audigier-Valette, C.; Sangha, R.; Urban, L.; Burgers, J. A.; Pluzanski, A.; Lee, K. Hyeong; Zurawski, B.; Schenker, M.; Peters, S.; Paz-Ares, L. G.; Borghaei, H.; O'Byrne, K. J.; Brahmer, J. R.; Gupta, R. G.; Bushong, J.; Li, L.; Yuan, Y.; Blum, S. I.; Reck, M.
errShare
errSave
Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errSkoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; Nishio, M.; Hafliger, S.; Lindsay, C.; Reinmuth, N.; Paulus, A.; Papakotoulas, P.; Obiozor, C.; Nduka, C.; Wang, Y.; De Langen, A. J.
errShare
errSave
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2024-09-01
err2
PREAI
errHochmair, Maximilian J.; Vermaelen, Karim; Mountzios, Giannis; Carcereny, Enric; Dooms, Christophe; Lee, Se-Hoon; Morocz, Eva; Kato, Terufumi; Ciuleanu, Tudor-Eliade; Dy, Grace K.; Parente, Barbara; O'Byrne, Kenneth J.; Chu, Quincy S.; De Castro Junior, Gilberto; Girard, Nicolas; Snyder, Wendy; Tran, Qui; Kormany, William; Houk, Brett; Mehta, Bhakti; Curioni-Fontecedro, Alessandra
errShare
errSave
BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin plus etoposide plus nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err1
PREAI
errKalinka, E.; Bahce, I.; Navarro Mendivil, A. F.; Ready, N.; Chu, Q. S-C.; Sugawara, S.; Sibille, A.; Provencio Pulla, M.; Johnson, M. L.; Hiltermann, J. T. J. N.; Ciuleanu, T-E.; Dziadziuszko, R.; Santo, A.; Zhang, Y.; Liu, Y.; Sarmiento, R.; Tannenbaum-Dvir, S.; Ojalvo, L.; Wu, J.; O'Byrne, K. J.
errShare
errSave
Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errKulasinghe, A.; Yan, R.; Quinn, S.; Falkenstein, B.; Monkman, J.; O'Byrne, K. J.; Chennubhotla, S. C.; Pullara, F.
errShare
errSave
KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errGarassino, M. C.; Janne, P. A.; Barlesi, F.; Spira, A. I.; Mok, T. S. K.; Hochmair, M.; O'Byrne, K. J.; Felip, E.; Kim, S-W.; Cappuzzo, F.; Naidoo, J.; Safadi, M.; Wamil, B.; He, J.; Reck, M.
errShare
errSave
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
errJTO CLINICAL AND RESEARCH REPORTS
IF3.5
err2024-09-01
err0
errOAAI
errItchins, Malinda; Liang, Shirley; Brown, Chris; Barnes, Tristan; Marx, Gavin; Chin, Venessa; Kao, Steven; Yip, Po Yee; Mersiades, Antony J.; Nagrial, Adnan; Bray, Victoria; Peters, Geoffrey; Parakh, Sagun; Garg, Kavita; Li, Bob T.; Mckay, Matthew; O'Byrne, Kenneth; John, Thomas; Gill, Anthony J.; Molloy, Mark P.; Solomon, Benjamin J.; Pavlakis, Nick
errShare
errSave
Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errO'Byrne, K. J.; Zhang, Y.; Ouyang, J.; Chou, W-C.; Chou, C-H.; Wu, J.; Adelakun, O.; Hollmann, T.; Zeng, J. A.; Corrella, L.; Metzler, M.; Green, C.; Sarmiento, R.; Lees, E.; Liu, Y.; Ojalvo, L.; Wu, B.
errShare
errSave
Lung cancer (internet-based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer
errRESPIROLOGY
IF6.3
err2024-08-13
err1
errOAAI
errNash, Jessica; Stone, Emily; Vinod, Shalini; Leong, Tracy; Dawkins, Paul; Stirling, Rob G.; Harden, Susan; Bolton, Alison; Mcwilliams, Annette; O'Byrne, Kenneth; Wright, Gavin M.; Brunelli, Vanessa N.; Guan, Tracey; Philpot, Shoni; Navani, Neal; Brims, Fraser
errShare
errSave
Glycan Profiling in Small Extracellular Vesicles with a SERS Microfluidic Biosensor Identifies Early Malignant Development in Lung Cancer
errADVANCED SCIENCE
IF14.1
err2024-06-17
err1
errOAAI
errZhou, Quan; Niu, Xueming; Zhang, Zhen; O'Byrne, Kenneth; Kulasinghe, Arutha; Fielding, David; Moller, Andreas; Wuethrich, Alain; Lobb, Richard J.; Trau, Matt
errShare
errSave
The expression and role of the Lem-D proteins Ankle2, Emerin, Lemd2, and TMPO in triple-negative breast cancer cell growth
errFRONTIERS IN ONCOLOGY
IF3.3
err2024-04-24
err0
errOAAI
errRose, Maddison; Burgess, Joshua T.; Cheong, Chee Man; Adams, Mark N.; Shahrouzi, Parastoo; O'Byrne, Kenneth J.; Richard, Derek J.; Bolderson, Emma
errShare
errSave
Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer
errCLINICAL & EXPERIMENTAL METASTASIS
IF3.2
err2024-02-28
err1
errOAAI
errWiegmans, A. P.; Ivanova, E.; Naei, V. Y.; Monkman, J.; Fletcher, J.; Mullally, W.; Warkiani, M. E.; O'Byrne, K.; Kulasinghe, A.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
A
Adrian L. Harris
H-index: 187 · Papers: 2.1K
P
Pasi A. Jänne
H-index: 163 · Papers: 2.3K
H
Harvey I. Pass
H-index: 153 · Papers: 1.4K
J
James Chih‐Hsin Yang
H-index: 141 · Papers: 1.2K
Y
Yi‐Long Wu
H-index: 135 · Papers: 2.2K
View more